Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ShionogiSGIOF 81 EV-to-FCF is 31.51 as of Aug. 18, 2026, which is 102% above its 10-year median of 15.57. GuruFocus rates SGIOF with a GF Score™ of 81/100 and a GF Value™ of $20.69 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 560 Drug Manufacturers companies, Shionogi ranks worse than 63.93% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Shionogi's Enterprise Value is $15,422 Mil.
Shionogi's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2026 was $489 Mil. Therefore, Shionogi's EV-to-FCF for today is 31.51.
The historical rank and industry rank for Shionogi's EV-to-FCF or its related term are showing as below:
SGIOF'
s EV-to-FCF Range Over the Past 10 Years
Min: 8.06 Med: 15.57 Max: 57.79
Current: 32.83
During the past 13 years, the highest EV-to-FCF of Shionogi was 57.79. The lowest was 8.06. And the median was 15.57.
SGIOF's EV-to-FCF is ranked worse than 63.93% of 560
companies
in the Drug Manufacturers industry
Industry Median: 21.44
vs SGIOF: 32.83
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Shionogi's share price for today is $17.90.
Shionogi's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.975.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Shionogi EV-to-FCF Related Terms
Shionogi EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Shionogi's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Shionogi's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shionogi EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Shionogi's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Shionogi's EV-to-FCF falls into.
Shionogi's current Enterprise Value is $15,422 Mil.
Shionogi's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $489 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shionogi (SGIOF) has a EV-to-FCF of 31.51 as of Aug. 18, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Shionogi and its competitors. This is 102% above median its historical median of 15.57. Over the past decade, Shionogi's EV-to-FCF has ranged from 8.06 to 57.79. According to the industry distribution chart, Shionogi ranks #358 out of 560 companies in the Drug Manufacturers industry, placing it in the top 63.9%.
Is Shionogi's EV-to-FCF too high?
Shionogi's current EV-to-FCF of 31.51 is 102% above median its 10-year median of 15.57. Over the past 10 years, this metric has ranged from a low of 8.06 to a high of 57.79. The Drug Manufacturers industry median EV-to-FCF is 21.44. Shionogi's value of 31.51 is 47% above this industry median. Based on the distribution chart, Shionogi ranks #358 out of 560 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Shionogi has a GF Score™ of 81/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Shionogi's EV-to-FCF compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Shionogi ranks #358 out of 560 companies for EV-to-FCF. This places Shionogi in the lower half of its industry. The industry median EV-to-FCF is 21.44. Shionogi's value of 31.51 is 47% above this benchmark. Historically, Shionogi's own EV-to-FCF has ranged from 8.06 to 57.79 over the past decade. While the company's 10-year median is 15.57 vs. the industry median of 21.44, Shionogi has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 21.44, based on 560 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shionogi's current EV-to-FCF of 31.51 is 47% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Shionogi and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 21.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shionogi's current EV-to-FCF is 31.51, which is 102% above median its own 10-year median of 15.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shionogi stock overvalued right now?
Based on GuruFocus' analysis, Shionogi (SGIOF) is currently considered Modestly Undervalued. The stock's GF Value™ is $20.69, compared to a current price of $17.90 — trading 13.5% below its estimated fair value. The current EV-to-FCF is 31.51, which is 102% above median its 10-year median of 15.57 and 47% above the Drug Manufacturers industry median of 21.44. Shionogi's overall GF Score™ is 81/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Shionogi (SGIOF), the current EV-to-FCF is 31.51 as of Aug. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shionogi (SGIOF) Overvalued in 2026?
Based on GuruFocus' analysis, Shionogi stock appears to be undervalued.
The current stock price of $17.90 is trading 13.5% below its estimated GF Value™ of $20.69.
GuruFocus considers Shionogi to be Modestly Undervalued.
Key valuation signals for SGIOF:
EV-to-FCF: 31.51 (102% above median its 10-year median of 15.57)
GF Value™: $20.69 vs. price of $17.90 (13.5% below fair value)
Industry Position: 47% above the Drug Manufacturers median (#358 of 560)
No single metric tells the full story. See the SGIOF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shionogi & Co Ltd is a specialty and generic drug manufacturing company. The company focuses on the manufacturing and distribution of pharmaceuticals, diagnostic reagents, and medical devices. The company engages in manufacturing, formulation, packaging, and analysis as part of its commercialization research that spans late-stage drug discovery through commercial production. It provides products and services in Japan, Europe, North America, and other regions.
81GF Score
Get the complete analysis for SGIOF
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SGIOF has been successfully added to your 
